1
|
K TASL, Chidurala R, Parepalli S, VP K. Green tea extract and hydroxyl-chloroquine combination enhances apoptosis in A549 non-small cell lung cancer cells. Bioinformation 2023; 19:860-865. [PMID: 37908618 PMCID: PMC10613812 DOI: 10.6026/97320630019860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 08/31/2023] [Accepted: 08/31/2023] [Indexed: 11/02/2023] Open
Abstract
Polyphenols, including catechins from green tea extract, have long been known for their potential anti-tumour activities. However, the precise mechanisms underlying their actions remain unclear. This study aimed to investigate the effects of green tea extract on A549 cells, a type of non-small lung cancer cells. A549 cells treated with green tea extract (GTE) were examined using an inverted light microscope and a fluorescence microscope. Cell sensitivity was evaluated using the MTT assay, while cell death was assessed using the Tali image-based cytometer. Ultra structural changes were observed using a transmission electron microscope. The findings suggested that even at the highest dose tested (150 µM), GTE did not exhibit toxic effects on A549 cells. Likewise, treatment with GTE resulted in a minimal, dose-dependent increase in the population of apoptotic cells. However, the analysis of cell structures using light and electron microscopy revealed an enhanced accumulation of vacuole-like structures in response to GTE. Moreover, under the fluorescence microscope, an increase in acidic vesicular organelles and the formation of LC3-II puncta were observed following GTE treatment. Assessment of autophagy function indicated that GTE-induced autophagy may serve as a self-protective mechanism against cytotoxicity, as blocking autophagy with bafilomycin A1 reduced cell viability and enhanced necrotic cell death in response to GTE treatment. In summary, our results demonstrate that A549 cells are insensitive to both low and high concentrations of green tea extract, likely due to the induction of cytoprotective autophagy. These findings suggest that the potential utility of GTE in lung cancer therapy may lie in its synergistic combinations with drugs or small molecules that target autophagy, rather than as a standalone therapy.
Collapse
Affiliation(s)
- Tanmayi Atchuta Sri Lakshmi K
- />SRMC and RI, Sri Ramachandra Institute of Higher Education and Research-DU, Porur, Chennai-600116, Tamil Nadu, India
| | - Rahul Chidurala
- />SRMC and RI, Sri Ramachandra Institute of Higher Education and Research-DU, Porur, Chennai-600116, Tamil Nadu, India
| | - Suresh Parepalli
- />Department of Pharmacology, SRMC and RI, Sri Ramachandra Institute of Higher Education and Research-DU, Porur, Chennai-600116, Tamil Nadu, India
| | - Karthik VP
- />Department of Pharmacology, SRMC and RI, Sri Ramachandra Institute of Higher Education and Research-DU, Porur, Chennai-600116, Tamil Nadu, India
| |
Collapse
|
2
|
MotieGhader H, Tabrizi-Nezhadi P, Deldar Abad Paskeh M, Baradaran B, Mokhtarzadeh A, Hashemi M, Lanjanian H, Jazayeri SM, Maleki M, Khodadadi E, Nematzadeh S, Kiani F, Maghsoudloo M, Masoudi-Nejad A. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug–gene interaction networks analysis. Sci Rep 2022; 12:9417. [PMID: 35676421 PMCID: PMC9177601 DOI: 10.1038/s41598-022-13719-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 05/16/2022] [Indexed: 12/14/2022] Open
Abstract
Lung cancer is the most common cancer in men and women. This cancer is divided into two main types, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Around 85 to 90 percent of lung cancers are NSCLC. Repositioning potent candidate drugs in NSCLC treatment is one of the important topics in cancer studies. Drug repositioning (DR) or drug repurposing is a method for identifying new therapeutic uses of existing drugs. The current study applies a computational drug repositioning method to identify candidate drugs to treat NSCLC patients. To this end, at first, the transcriptomics profile of NSCLC and healthy (control) samples was obtained from the GEO database with the accession number GSE21933. Then, the gene co-expression network was reconstructed for NSCLC samples using the WGCNA, and two significant purple and magenta gene modules were extracted. Next, a list of transcription factor genes that regulate purple and magenta modules' genes was extracted from the TRRUST V2.0 online database, and the TF–TG (transcription factors–target genes) network was drawn. Afterward, a list of drugs targeting TF–TG genes was obtained from the DGIdb V4.0 database, and two drug–gene interaction networks, including drug-TG and drug-TF, were drawn. After analyzing gene co-expression TF–TG, and drug–gene interaction networks, 16 drugs were selected as potent candidates for NSCLC treatment. Out of 16 selected drugs, nine drugs, namely Methotrexate, Olanzapine, Haloperidol, Fluorouracil, Nifedipine, Paclitaxel, Verapamil, Dexamethasone, and Docetaxel, were chosen from the drug-TG sub-network. In addition, nine drugs, including Cisplatin, Daunorubicin, Dexamethasone, Methotrexate, Hydrocortisone, Doxorubicin, Azacitidine, Vorinostat, and Doxorubicin Hydrochloride, were selected from the drug-TF sub-network. Methotrexate and Dexamethasone are common in drug-TG and drug-TF sub-networks. In conclusion, this study proposed 16 drugs as potent candidates for NSCLC treatment through analyzing gene co-expression, TF–TG, and drug–gene interaction networks.
Collapse
|
3
|
Gürgen D, Conrad T, Becker M, Sebens S, Röcken C, Hoffmann J, Langhammer S. Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts. Commun Biol 2022; 5:59. [PMID: 35039644 PMCID: PMC8763947 DOI: 10.1038/s42003-022-03016-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 12/27/2021] [Indexed: 12/25/2022] Open
Abstract
Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patient's prognosis. Based on previously published criteria for selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft (PDX) tumors were treated with a low dose combination of cabozantinib, afatinib, plerixafor and etoricoxib. All PDX tumors treated, including highly therapy-resistant adeno- and squamous cell carcinomas without targetable oncogenic mutations, were completely suppressed by this drug regimen, leading to an ORR of 81% and a CBR of 100%. The application and safety profile of this low dose therapy regimen was well manageable in the pre-clinical settings. Overall, this study provides evidence of a relationship between active paracrine signaling pathways of the Cellular Tumorigenic Network, which can be effectively targeted by a low-dose multimodal therapy to overcome therapy resistance and improve prognosis of NSCLC.
Collapse
Affiliation(s)
- Dennis Gürgen
- EPO Experimental Pharmacology & Oncology, Berlin, Germany
| | | | - Michael Becker
- EPO Experimental Pharmacology & Oncology, Berlin, Germany
| | - Susanne Sebens
- Institute for Tumorbiology, University of Kiel, Kiel, Germany
| | | | - Jens Hoffmann
- EPO Experimental Pharmacology & Oncology, Berlin, Germany
| | | |
Collapse
|
4
|
Li X, Li F, Wang F, Li J, Lin C, Du J. Resveratrol inhibits the proliferation of A549 cells by inhibiting the expression of COX-2. Onco Targets Ther 2018; 11:2981-2989. [PMID: 29872310 PMCID: PMC5973427 DOI: 10.2147/ott.s157613] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Purpose The aim was to investigate resveratrol effects on A549 cells proliferation. Methods A total of 104 lung adenocarcinoma tissues and nontumor tissues were collected. BEAS-2B cells were cultured in RPMI 1640 medium (group A). A549 cells were treated with RPMI 1640 medium containing different resveratrol concentrations. A549 cells were transfected and grouped as follows: blank group, siRNA-negative control group, siRNA-COX-2 group and resveratrol + siRNA-COX-2 group. qRT-PCR and Western blot were conducted to detect COX-2 expression. MTT assay, soft agar clone assay and flow cytometry were performed to assess proliferation and cell cycle. Results The relative expression of COX-2 mRNA was significantly increased in lung adenocarcinoma tissues (P<0.01) and it was closely related with clinical stages. Resveratrol at 60 μmol/L significantly inhibited A549 cells proliferation, S phase cells proportion and COX-2 expression (P<0.01). COX-2 expression in siRNA-COX-2 group was significantly lower than that in blank group and siRNA-negative control group (P<0.01). OD570 values, colony formation rate and S phase cells proportion of resveratrol + siRNA-COX-2 group were much lower than those of other groups (P<0.01). Conclusion Resveratrol inhibits A549 cells proliferation by inhibiting COX-2 expression.
Collapse
Affiliation(s)
- Xia Li
- Respiratory Department of Internal Medicine, Rizhao People's Hospital of Shandong Province, Rizhao, Shandong, 276800, China
| | - Fang Li
- Respiratory Department of Internal Medicine, Rizhao People's Hospital of Shandong Province, Rizhao, Shandong, 276800, China
| | - Fangfang Wang
- Pulmonary Department, Affiliated Hospital of QingDao University, Qingdao, Shandong, 266003, China
| | - Jinfeng Li
- Pulmonary Department, Affiliated Hospital of QingDao University, Qingdao, Shandong, 266003, China
| | - Cunzhi Lin
- Pulmonary Department, Affiliated Hospital of QingDao University, Qingdao, Shandong, 266003, China
| | - Jianxin Du
- Pulmonary Department, Affiliated Hospital of QingDao University, Qingdao, Shandong, 266003, China
| |
Collapse
|
5
|
Langhammer S, Scheerer J. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget 2017; 8:43555-43570. [PMID: 28402937 PMCID: PMC5522169 DOI: 10.18632/oncotarget.16674] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Accepted: 03/13/2017] [Indexed: 12/26/2022] Open
Abstract
In the light of current treatment developments for non-small cell lung cancer (NSCLC), the idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways mediating resistances to targeted therapies is brought forward. Based on a review of available preclinical and clinical data in NSCLC combinational approaches to address drivers of this network with marketed drugs are discussed. Five criteria for selecting drug combination regimens aiming at its disruption and thereby overcoming resistances are postulated.
Collapse
|
6
|
Yu R, Han L, Ni X, Wang M, Xue P, Zhang L, Yuan M. Kruppel-like factor 4 inhibits non–small cell lung cancer cell growth and aggressiveness by stimulating transforming growth factor-β1-meidated ERK/JNK/NF-κB signaling pathways. Tumour Biol 2017. [PMID: 28631556 DOI: 10.1177/1010428317705574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- Renzhi Yu
- Department of Respiratory Medicine, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| | - Lei Han
- Department of Respiratory Medicine, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| | - Xin Ni
- Department of Respiratory Medicine, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| | - Minghuan Wang
- Community Health Service Center, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| | - Ping Xue
- Department of Respiratory Medicine, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| | - Li Zhang
- Department of Respiratory Medicine, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| | - Mei Yuan
- Department of Respiratory Medicine, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang, China
| |
Collapse
|
7
|
Srinivasan M, Rajabi M, Mousa SA. Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. NANOMATERIALS 2015; 5:1690-1703. [PMID: 28347089 PMCID: PMC5304767 DOI: 10.3390/nano5041690] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 09/23/2015] [Accepted: 10/01/2015] [Indexed: 01/05/2023]
Abstract
The field of nanotechnology has led to the development of many innovative strategies for effective detection and treatment of cancer, overcoming limitations associated with conventional cancer diagnosis and therapy. Multifunctional nanoparticle systems can integrate imaging, targeting and treatment moieties on the surface and in the core, resulting in targeted delivery of the imaging or treatment modalities, specifically to the tumor. Multifunctional nanoparticles also enable simultaneous delivery of multiple treatment agents, resulting in effective combinatorial therapeutic regimens against cancer. In this review, various multifunctional nanoparticle systems that feature a variety of targeting moieties for in vitro and/or in vivo cancer imaging and therapy are discussed.
Collapse
Affiliation(s)
- Mathangi Srinivasan
- The Pharmaceutical Research Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.
| | - Mehdi Rajabi
- The Pharmaceutical Research Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.
| | - Shaker A Mousa
- The Pharmaceutical Research Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.
| |
Collapse
|